Researchers have developed MT-125, a nonmuscle myosin II inhibitor that penetrates the brain, effectively reduces glioblastoma invasiveness, and sensitizes resistant tumors to kinase inhibitors and radiation. Preclinical models demonstrated doubled survival and durable remissions with combination therapies. This approach targets a convergence point in oncogenic signaling, providing a promising therapeutic avenue for this aggressive and treatment-refractory brain cancer.